Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes

Condition(s) studied

Investigational drug(s) / intervention(s)

Electronic Patient-Reported Outcome Monitoring: Participants complete the MDASI-LC and EQ-5D questionnaires electronically on a weekly basis during CRT and for 12 weeks after CRT. The data are used to evaluate symptom burden, symptom clusters, and symptom trajectories.

Study summary

This prospective observational study aims to evaluate symptom burden and symptom clusters among lung cancer patients undergoing definitive concurrent chemoradiotherapy (CRT), based on electronic patient-reported outcomes (ePROs). Patients will complete the validated MDASI-LC and EQ-5D instruments weekly from baseline through the end of CRT and for 12 weeks post-treatment. The study will characterize the longitudinal trajectories of symptom severity and interference, identify distinct symptom clusters and their temporal patterns, and explore patient-level predictors of symptom burden. The findings may support the development of personalized symptom management strategies and improve quality of life during and after CRT.

Eligibility

Primary outcome measure(s)

• Longitudinal trajectory of symptom burden over time based on M. D. Anderson Symptom Inventory-Lung Cancer — Baseline, weekly during CRT (weeks 1-6), and weekly for 12 weeks after CRT.
  M. D. Anderson Symptom Inventory-Lung Cancer:Scale range 0-10, with higher scores indicating worse symptom burden.

Trial sites (1)

More Qian Chu trials in China

Other trials for the same condition